Photo by Ion Fet on Unsplash
Photo by Ion Fet on Unsplash

Prevention of diabetic retinopathy within everyone’s reach

RetinaReadRisk is developing a platform for the early detection and diagnosis of diabetic retinopathy


Paradigm shift in diabetic retinopathy management

Diabetic retinopathy (DR) is a microvascular complication of type 1 and type 2 diabetes that affects the small vessels of the retina. DR can lead to complete vision loss if not detected early and is the major cause of preventable blindness in working-age adults.

Icon earth

Globally, DR is the fifth cause of blindness and visual impairment affecting between 3-4% of people in Europe. DR affects 30% of people with diabetes and it is estimated that 280 million people have lost their sight due to diabetes worldwide.

icon eye

When detected on time, the risk of DR can be reduced by 95% but the disease is asymptomatic in its early stages and the risk of developing DR varies among patients.

Icon hospital

DR can be prevented by controlling risk factors, such as glycemia or arterial hypertension. But existing healthcare systems are inefficient in detecting DR for several reasons as short supply of cameras or the fact that 29% of Europeans live outside urban areas, where ophthalmologist units are not located.

In RetinaReadRisk we are developing a new platform for the early detection and diagnosis of DR in rural areas.

The solution stems originally from an European project funded by EIT Health with a Consortium constituted by 7 partners: the Institut d’Investigació Sanitària Pere Virgili, the Institut Català de la Salut, GENESIS Biomed , Telefónica SA, Grupo TRC, and the French organizations Fondation de l’Avenir and E’Seniors.

The solution combines artificial intelligence (AI) models and 5G technologies, that would enable the capture of images at medical offices closest to the population by smart phone. The deep learning models and AI will automatically analyze DR image, helping to predict the risk of a person developing DR.

Retina Read Risk work process


Josep Lluís Falcó

Josep Lluís Falcó

Josep Lluís has 20 years’ experience in the biomedical sector. He has worked for big pharma companies (Sanofi), mid-size pharmas (Ferrer Grupo), small biotechs (Hospital spin-off), tech transfer offices (Fundació Bosch i Gimpera) and consulting firms (Antares Consulting and Asphalion). He has also been associate professor at IQS. His experience is based on healthcare strategy, technology transfer, fundraising of start-up companies, business development, marketing, market access, reimbursement and regulatory affairs.

Josep Lluís founded GENESIS Biomed in 2017. GENESIS Biomed is a consultancy firm in the biomedical healthcare sector specialising in providing consulting services to spin-off and start-up companies, entrepreneurs and research centres. Among the services offered is that of interim CEO for start-ups.

Josep Lluís has founded four companies. He currently serves as board member for three start-up companies and he is mentor of several entrepreneurs. In addition, in the last five years he has been involved in 19 private fundraising processes and he has contributed to raising 67 million euros for his clients.

Newsroom of
Retina Read Risk

RetinaReadRisk is developing a platform for the early detection and diagnosis of diabetic retinopathy

RetinaReadRisk is developing a platform for the early detection and diagnosis of diabetic retinopathy

The test to detect diabetic retinopathy is an examination of the fundus of the eye. In Catalonia it is carried out in certain primary care centers (CAP), mostly located in cities. In the future, the aim is to put the technology that will commercialize the spin- off at the service of all CAPs so that …

    Supported by

    We are grateful to our sponsors and partners for their support, commitment and trust in the project

    Spin-Off from IISPV

    Other founders


    Public funds